<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02098967</url>
  </required_header>
  <id_info>
    <org_study_id>NP28903</org_study_id>
    <secondary_id>RG7775</secondary_id>
    <nct_id>NCT02098967</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.</brief_title>
  <official_title>A Multi-Center, Open-Label, First-in-Human, Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6839921, An MDM2 Antagonist, Following Intravenous Administration in Patients With Advanced Malignancies, Including Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This open label, Phase I study of RO6839921 is a dose-escalation study with two arms. Prior&#xD;
      to investigations in either arm, patients in a single cohort, Cohort 0, will receive&#xD;
      non-escalating, intravenous (IV) doses of RO6839921 daily on Days 1-5 of a 28-day cycle.&#xD;
      Interim PK and safety data from this cohort will be evaluated before initiating&#xD;
      dose-escalation.&#xD;
&#xD;
      In arm A, RO6839921 will be given to patients with advanced solid tumor malignancies. In Arm&#xD;
      B, RO6839921 will be given to patients with relapsed/refractory acute myeloid leukemia (AML).&#xD;
      The arms will escalate independently. Escalation will begin in solid tumor patients (Arm A)&#xD;
      in single patient cohorts, using a new Continual Reassessment Method (n-CRM). Escalation for&#xD;
      AML patients will be initiated at or below the dose level that causes &gt;/= Grade 2 hematologic&#xD;
      side effects in Arm A. Escalation in AML patients will follow a rolling 6 design.&#xD;
&#xD;
      In both arms, RO6839921 will be administered by IV infusion on Days 1-5 of 28-day cycles.&#xD;
&#xD;
      There will be no intrapatient dose escalation. All patients may be treated until disease&#xD;
      progression/relapse or unacceptable toxicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 21, 2014</start_date>
  <completion_date type="Actual">May 7, 2018</completion_date>
  <primary_completion_date type="Actual">May 7, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities</measure>
    <time_frame>Approximately 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma area under the concentration-time curve (AUC) of RO6839921.</measure>
    <time_frame>Up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum macrophage inhibitory cytokine-1 (MIC-1) expression measured by enzyme-linked immunosorbent assay (ELISA)</measure>
    <time_frame>Up to Day 22</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Neoplasms, Myelogenous Leukemia, Acute</condition>
  <arm_group>
    <arm_group_label>Acute myeloid leukemia patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Solid tumor patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO6839921</intervention_name>
    <description>Non-escalating IV doses given on Days 1-5 of Cycle 1.</description>
    <arm_group_label>Cohort 0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO6839921</intervention_name>
    <description>Escalating IV doses of RO6839921 in solid tumor patients. Dose escalation will be calculated using the new Continual Reassessment Method (nCRM). RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.</description>
    <arm_group_label>Solid tumor patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO6839921</intervention_name>
    <description>Escalating IV doses of RO6839921 in AML patients. Escalation will follow an adapted rolling 6 design. Starting dose &lt;/= dose inducing Grade 2 toxicity in patients with solid tumors. RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.</description>
    <arm_group_label>Acute myeloid leukemia patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cohort 0 and Arm A&#xD;
&#xD;
          -  Patient must have histologically or cytologically confirmed advanced cancer for which&#xD;
             standard cures or relieving measures either do not exist, are ineffective or are not&#xD;
             acceptable to the patient.&#xD;
&#xD;
          -  Measureable disease according to RECIST criteria version 1.1.&#xD;
&#xD;
          -  ECOG performance status of 0 to 1.&#xD;
&#xD;
          -  Adequate bone marrow function.&#xD;
&#xD;
        Arm B&#xD;
&#xD;
          -  Patients with documented acute myeloid leukemia (AML), except for acute promyelocytic&#xD;
             leukemia.&#xD;
&#xD;
          -  Patients with relapsed/refractory AML or patients who have not received prior therapy&#xD;
             who are high risk according to European LeukemiaNet (ELN) criteria.&#xD;
&#xD;
          -  ECOG performance status of 0 to 2.&#xD;
&#xD;
        For Cohort 0, Arms A and B&#xD;
&#xD;
          -  Life expectancy of &gt;/= 12 weeks.&#xD;
&#xD;
          -  Age &gt;/= 18 years or older.&#xD;
&#xD;
          -  All patients must be willing to use effective methods of contraception until 10 days&#xD;
             after the last dose; women must not be pregnant or breast-feeding.&#xD;
&#xD;
          -  Adequate renal and hepatic function.&#xD;
&#xD;
          -  Patients with stable central nervous system (CNS) tumors are eligible.&#xD;
&#xD;
          -  There are no requirements or limitations on the amount or type of prior&#xD;
             anti-tumor/anti-leukemia therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Cohort 0 and Arm A&#xD;
&#xD;
          -  Patients with a history of any form of leukemia except for Stage 0 and 1 chronic&#xD;
             lymphocytic leukemia (CLL) not requiring treatment.&#xD;
&#xD;
          -  Patients receiving any cancer treatment within 21 days of start of study medication.&#xD;
             Patients must also have recovered from severe side effects due to prior treatment&#xD;
             before study start.&#xD;
&#xD;
          -  Patients with known bone marrow disorders that may interfere with bone marrow&#xD;
             recovery, or patients with delayed recovery from prior chemoradiotherapy.&#xD;
&#xD;
          -  Patients with known bleeding or clotting disorders or non-drug-induced low platelet&#xD;
             count.&#xD;
&#xD;
        Arm B&#xD;
&#xD;
        - Patients receiving any cancer treatment within 14 days of start of study medication.&#xD;
        Hydroxyurea may be taken until first administration of the study drug. Patients must also&#xD;
        have recovered from severe side effects due to prior treatment before study start.&#xD;
&#xD;
        For Cohort 0, Arms A and B&#xD;
&#xD;
          -  Patients receiving any other test drugs within 30 days of start of study medication&#xD;
&#xD;
          -  Patients receiving the cytochrome P450 inhibitors, substrates or inducers specified in&#xD;
             the protocol.&#xD;
&#xD;
          -  Anticoagulation or antiplatelet treatment must be discontinued 7 days prior to start&#xD;
             of study medication.&#xD;
&#xD;
          -  Patients who have received hormonal therapy (except for prostate cancer treatment and&#xD;
             hormone replacement therapy) within the 2 weeks prior to start of study medication.&#xD;
&#xD;
          -  Patients with evidence of electrolyte imbalance, which may be treated to meet&#xD;
             eligibility.&#xD;
&#xD;
          -  Serum albumin &lt; 2.8 g/dL.&#xD;
&#xD;
          -  HIV-positive patients who are currently receiving combination antiretroviral therapy.&#xD;
&#xD;
          -  Patients who have any severe and/or uncontrolled medical conditions or other&#xD;
             conditions that could affect their participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina; Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network; Princess Margaret Hospital; Medical Oncology Dept</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital / McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>March 25, 2014</study_first_submitted>
  <study_first_submitted_qc>March 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2014</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

